arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ALLURION TECHNOLOGIES, INC.

ALUR
— Price unavailable
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
5 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

ALLURION TECHNOLOGIES, INC. faces fundamental challenges with weakness in Profit Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap —
Dividend Yield —
Revenue Growth -52.6% ↘
Op. Margin -198.0% ↘
ROIC 39.2% ↘
FCF / Share $-3.84 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$15.23M
↓ -52.6% —
Net Income Profit after all expenses
$-28.75M
↓ -10.0% —
Operating Margin Operating profit as % of sales
-198.0%
↓ -26.7% 0th
FCF / Share Free cash flow per share
$-3.84
↑ +79.9% —
Long-Term Debt Long-term obligations
$35.71M
↑ +1050.8% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
95
Cash Quality ↓
66

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 18 quarters